Found 1998 clinical trials
A Clinical Trial for individuals suffering from Hyperlipidemia (high cholesterol) and are at risk of cardiovascular events (ie: heart attack, stroke, angina.
A Clinical Trial for individuals suffering from Hyperlipidemia (high cholesterol) and are at risk of cardiovascular events (ie: heart attack, stroke, angina.
- 687 views
- 23 Nov, 2020
- 1 location
EX9924-4473: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
Oral Semaglutide
- 171 views
- 23 Nov, 2020
- 1 location
A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus.
A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in
- 70 views
- 23 Nov, 2020
- 1 location
DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
- 170 views
- 25 Mar, 2021
- 1 location
GUIDE-IT - GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) -The goal of this US prospective outpatient AF registry is to identify real world treatment patterns in patients with AF(atrial fibrillation), outside of randomized controlled trials. Specifically, the registry will attempt to define current treatment patterns and their relationship with outcomes, including stroke, all-cause mortality, and quality-of-life.
, including stroke, all-cause mortality, and quality-of-life.
- 129 views
- 25 Mar, 2021
- 2 locations
A randomized, double-blind, placebo-controlled multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease
risks of Cardiovascular Disease such as heart attacks and strokes.
- 0 views
- 31 May, 2022
- 1 location
- 0 views
- 11 Aug, 2022
- 1 location
ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
- 100 views
- 25 Mar, 2021
- 1 location
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
- 92 views
- 25 Mar, 2021
- 1 location
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, and associated outcomes.
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, …
- 93 views
- 08 Nov, 2020
- 1 location